Meta-analysis finds high persistence after switching infliximab route in pediatric IBD

The systematic review and meta-analysis was published 17 October 2026 in Current Gastroenterology Reports.

Stands on 1 first-party reading of PubMed and ClinicalTrials.gov, not reporting.

A systematic review and meta-analysis examining switch from intravenous to subcutaneous infliximab in children with inflammatory bowel disease was published 17 October 2026, per PubMed listings.^[1] The analysis included 173 patients across studies spanning 18 years. Authors reported pooled treatment persistence of 92% (95%CI 84-98). Maintained clinical remission was 93% (95%CI 84-99). Any-cause discontinuation was 8% (95%CI 2-16). Discontinuation occurred most often for injection-site intolerance, disease relapse, or paradoxical dermatitis. The work received funding from NIDDK NIH HHS. The paper carries PubMed identifier 42891908.

Proof1 source · 1 publisher · signed

What this stands on

"Switching from Intravenous to Subcutaneous Infliximab in Children with Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis." published in Current gastroenterology reports as a meta-analysis (PubMed 42891908, doi 10.1007/s11894-026-01061-2). Sample: 173 as stated in the abstract. Duration: 18 years. Results as the authors report them: Random-effects proportional meta-analysis yielded pooled treatment persistence of 92% (95%CI 84-98), maintained clinical remission of 93% (95%CI 84-9 · PubMed and ClinicalTrials.gov, read by the New studies instrument · the fact recordUnited Statesofficial source

Read directly from PubMed and ClinicalTrials.gov, the public registries of published studies and registered trials, not from anyone's report of it.